Study: Cannabis Use Associated With Lower Risk Of Atrial Fibrillation Among Patients Hospitalized For Heart Failure

NEW YORK: Cannabis exposure is associated with lower instances of atrial fibrillation (arrhythmia) in patients hospitalized for heart failure, according to data published in the American Journal of Cardiology.

A team of investigators from Seton Hall University, the University of Alabama at Birmingham, and elsewhere assessed the relationship between cannabis exposure and atrial fibrillation in a cohort of nearly four million patients hospitalized in 2014 for heart failure.

Compared to matched controls, “Cannabis users have lower odds of AF [than do] nonusers, which was not explained by co-morbid conditions, age, insurance type, [or] socioeconomic status,” authors concluded.

A prior analysis by the team similarly reported that cannabis exposure lowered the risk of atrial fibrillation and also reduced in-hospital mortality in heart failure patients.

Other studies have similarly reported that marijuana-exposed patients are less likely than non-users to die when hospitalized for burns and other forms of severe trauma, certain types of orthopedic surgeries, and traumatic brain injury.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Relation of cannabis use and atrial fibrillation among patients hospitalized for heart failure,” appears in the American Journal of Cardiology.

GB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease

NEVADA: GB Sciences has announced that its wholly-owned subsidiary, Growblox Life Sciences has licensed intellectual property from Makai Biotechnology, LLC. The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.

“GB Sciences is a drug discovery company focused on the development of novel therapeutics based on cannabinoids, terpenoids, and flavonoids from cannabis plants, and is naturally positioned to develop this intellectual property into new medicines. Licensing this TRPV1 patent underscores our drug discovery commitment to targeting the non-classical cannabinoid receptors, beyond the usual CB1 and CB2 receptors,” says Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. “Our vision of novel, patentable cannabis-based formulations in the treatment of major diseases is now married with a proven drug target for modulation of adverse outcomes in cardiovascular disease.  Cannabinoids in native plant extracts exerted a more significant effect on TRPV1 receptors than purified cannabinoids in published research reports, and GB Sciences’ cannabis-plant-based approach may provide additional clinical benefits to patients due to the ‘entourage effect’. In addition, the side effect profiles of cannabis-based therapies have generally been well tolerated.”

“Cardiovascular disease is the leading global cause of death, accounting for more than 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030. In the US, this equates to one in three deaths, about one every 40 seconds, and costs the US approximately $316.6 billion a year. Patients urgently need new drug regimens that can ameliorate or reverse the stages of cardiac hypertrophy and heart failure,” says Dr. Alexander Stokes, Founder and President of Makai Biotechnology. “TRPV1 is clearly a major mechanistic player in the progression to heart failure, and there is great potential for proprietary mixtures within the GB Life Sciences portfolio to regulate the TRPV1 cannabinoid receptor.”